|
| | | | | | | | | | |
| Brand | Indication | MOA | Phase | Economics | | | Price | 41.63 | |
| NTLA-2001 | ATTR amyloidosis | CRISPR | I/II | REGN | | | Shares | 85.28403899999999 | Q322 |
| NTLA-2002 | HAE | CRISPR | II in 2023 | | | | MC | 3550.37454357 | |
| NTLA-3001 | AATD | CRISPR insertion | IND in 2H23 | | | | Cash | 1178.829 | Q322 |
| NTLA-5001 | AML | TCR | | | | | Debt | 0 | Q322 |
| | Hemophilia A | | | | | | EV | 2371.5455435699996 | |
| | Hemophilia B | | | | | | | | |
| | Primary Hyperoxaluria | | | | | | AD | 1898.091 | Q322 |
| NTLA-6001 | CD30+ lymphomas | | | | | | PIC | 1063.78 | Q322 |
| | Sickle Cell | | | NVS | | | | | |
| | | | | | | | | | |
| YE23: initiate pivotal trial for NTLA-2001 | | | 11/30/2022: Proposes secondary. | | | | CEO: John Leonard | | |
| | | | 11/30/2022: Prices secondary of 6.6m at 45.80 for $300m gross. | | | | | | |
| | | | | | | | | | |
| | | | 4/11/2016: REGN deal. $75m upfront. | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| Rewrite Therapeutics acquisition | | | | | | | | | |
| AvenCell Therapeutics investment, privately held CART company, formed with Cellex | | | | | | | | | |
| SparvingVision (ocular) | | | | | | | | | |
| Regeneron: ATTR is 1st of 10 liver targets, hemophilia A/B included | | | | | | | | | |
| Kyverna (CD19 cell therapy) | | | | | | | | | |
| ONK Therapeutics | | | | | | | | | |
| Novartis | | | | | | | | | |